Sociedad Americana de Hirudoterapia

Post-Stroke Hemiplegia (Investigational Adjunct)

Investigational adjunct to physical/occupational therapy in chronic post-stroke hemiplegia; no RCT support; not for acute stroke care.

Tier C — InvestigationalInvestigacionalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?
Not FDA-cleared for post-stroke hemiplegia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for post-stroke hemiplegia is investigational.
¿Qué evidencia existe?
Tier C (investigational). Only anecdotal reports; there are no randomized controlled trials. Evidence-based stroke rehabilitation per AHA/ASA guidelines: structured inpatient or outpatient rehabilitation, constraint-induced movement therapy, repetitive task training, mirror therapy, robot-assisted therapy, functional electrical stimulation, and botulinum toxin for spasticity. Antiplatelet (aspirin, clopidogrel) or anticoagulant therapy for secondary prevention. Statin, blood pressure control, and lifestyle modification.
Riesgos principales
  • Bleeding from bite sites for 6 to 24 hours after detachment, prolonged on antiplatelet or anticoagulant
  • Severe bleeding risk on dual antiplatelet or anticoagulant therapy (post-stroke standard)
  • Worsening of spasticity or neurogenic pain
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Risk in patients with marginal cerebral perfusion (transient symptom worsening)
  • Substitution for evidence-based rehabilitation and secondary prevention
  • Delay of constraint-induced movement therapy, botulinum toxin for spasticity, or rehab milestones
Quién no debería considerar esto
  • Patients on dual antiplatelet (aspirin + clopidogrel) or anticoagulant therapy (absolute contraindication)
  • Patients within 3 months of acute stroke (recovery window — focus on rehab)
  • Patients with severe spasticity or contracture requiring physiatry evaluation
  • Patients with active depression, post-stroke psychiatric symptoms (treat first)
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients who have not engaged with structured stroke rehabilitation
Qué preguntar a su clínico
  • Am I engaged with structured outpatient stroke rehabilitation?
  • Have I been offered constraint-induced movement therapy or robot-assisted therapy?
  • Am I a candidate for botulinum toxin injection for spasticity?
  • What are my current antiplatelet or anticoagulant therapies, and is the bleeding risk acceptable?
  • What evidence specifically supports leech therapy for stroke recovery?
  • Has my secondary prevention been optimized (statin, blood pressure, lifestyle)?
  • What is the cost and is it covered by insurance? (typically not covered)
Cuándo buscar atención urgente
  • Sudden new weakness, numbness, slurred speech, or vision loss (possible recurrent stroke)
  • Sudden severe headache (worst of life — rule out hemorrhage)
  • Chest pain, shortness of breath (possible cardiac event)
  • Severe bleeding from any site (anticoagulant overdose or interaction)
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

Qué NO significa esto

  • This is NOT FDA-cleared for post-stroke hemiplegia.
  • Anecdotal reports do NOT establish efficacy versus structured rehabilitation, constraint-induced movement therapy, or botulinum toxin.
  • It does NOT substitute for evidence-based stroke rehab during the critical recovery window.
  • It does NOT address antiplatelet or anticoagulant therapy that is essential for secondary prevention — and these therapies make leech bleeding much more dangerous.
  • It does NOT replace structured rehabilitation that has decades of evidence.

Clinical Profile

Category
neurological
ICD-10
I69.351, I69.352, I69.353, I69.359
Safety tier
high

Evidence Summary

Post-stroke hemiplegia management is dominated by neurorehabilitation (constraint-induced movement therapy, mirror therapy, robotic rehabilitation, task-specific training) per AHA/ASA 2016 guidelines. No controlled clinical trial of leech therapy for post-stroke hemiplegia has been published, and it has no established role in motor recovery; any use would be investigational only. A critical safety constraint applies: most post-stroke patients take antiplatelet or anticoagulant therapy for secondary prevention, an absolute exclusion for leech therapy. Leech application is not a substitute for evidence-based rehabilitation.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Zhernov VA et al. (2012)0

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Active deep vein thrombosis (acute phase <2 weeks)
  • Critical limb ischemia (ABI <0.4)
  • Antiplatelet or anticoagulant therapy for secondary stroke prevention
  • Acute or subacute stroke (<3 months from onset)
  • Hemorrhagic stroke history
  • Uncontrolled hypertension (SBP >180)
  • Severe cognitive impairment limiting consent

Related Conditions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

Post-Stroke Hemiplegia (Investigational Adjunct) — Hirudotherapy Evidence | ASH